Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for...
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH‐Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort
About this item
Full title
Author / Creator
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
IDH‐mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear.
Methods
In a large cohort of patients with histologically proven 2016 World Health Organizatio...
Alternative Titles
Full title
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH‐Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8100568
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8100568
Other Identifiers
ISSN
1083-7159
E-ISSN
1549-490X
DOI
10.1002/onco.13701
